Recon: NICE Backs Merck's Prevymis for CMV; China's Hansoh Pharma Eyes $1B IPO - Regulatory Focus
Recon: NICE Backs Merck's Prevymis for CMV; China's Hansoh Pharma Eyes $1B IPO Regulatory Focus
Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Merck's R&D boss sees more promise in his big ...
Comments
Post a Comment